Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2011-04-07
Target enrollment:
Participant gender:
Summary
Primary Objective:
Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide,
and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle
cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be
assessed.
Secondary Objectives:
1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell
lymphoma.
2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma
during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated
with clinical response to RT-PEPC therapy.
3. Assess the quality of life of patients receiving RT-PEPC treatment